Zachary Pitluk, Ph.D., Vice President of Life Sciences and Healthcare at Paradigm4, highlights how real insight comes, not from data collection, but from intelligent data curation, computation, and application.
Category: Company News
Bio-IT World || The Role Of Bioinformatics In Bringing Biobanks To The Forefront Of Scientific Breakthroughs
Life science researchers and drug discovery scientists today work in what, in my view, will be remembered in the future as the beginning of a “golden era” where the power of genetic information is connected to a wide range of other healthcare and lifestyle data to support better understanding of disease etiology
Biospace || Paradigm4 Joins the Tetra Partner Network to Leverage Tetra Data into High-performing Analytical Computing Applications for Pharmaceutical Customers
TetraScience, the R&D Data Cloud company, announced today that Paradigm4, an integrated scientific data analytics company, has joined the Tetra Partner Network (TPN) so that pharmaceutical customers can accelerate research decision-making using Tetra Data as a foundation for analytical computing.
International Pharmaceutical Technology | 1 Trillion Cells, 50 Million Individuals
Calculating the true value of scientific data storage platforms is the goal of every developer. With millions of cells to analyze, digital solutions are the key
Pharma’s Almanac | What do you think most differentiates the U.S. pharma/biopharma industry or the market?
Paradigm4’s Marilyn Matz reflects on the understanding complex biological phenomena has required concurrent advances in experimental methods and computing power.
Pharma’s Almanac | Integrating Heterogeneous Data to Enable Precision Medicine
Paradigm4’s Marilyn Matz and Zachary Pitluk discuss the challenges of integrating data from heterogeneous sources and how the company’s plaform and apps combine the cutting edge of computer science and a sensibility geared toward the unique needs of pharma and biopharma to provide end-to-end solutions.
Manufacturing Chemist | Multidimensional data analysis platforms: meeting new FDA calls for consistent evidence from CGT developers
Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns
Biocompare | Are We Ready to Embrace Precision Medicine?
Precision medicine is one of the most talked about trends in healthcare. The promise is improved health outcomes and patient satisfaction, gained through an understanding of individual variability in genes, environment, and lifestyle. Recent commentators suggest that many of the technologies required to realize this goal already exist—and predict much wider application can be achieved by 2030.
At the heart of a precision medicine approach is data—huge amounts of data.
Drug Discovery World | Are scalable data science platforms the way forward?
Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets.
Clinical Laboratory | Paradigm4 unveils analytical development data management tool to unlock Allotrope data format (ADF) ‘treasure trove’
Addressing the vital economic challenge of uncovering new critical quality attributes (CQAs), Paradigm4’s REVEALTM Analytical Development app enables data analysts…